<DOC>
	<DOCNO>NCT00887354</DOCNO>
	<brief_summary>This study evaluate whether teriparatide superior active comparator change baseline lumbar spine BMD ( bone mineral density ) men postmenopausal woman low bone mass recent pertrochanteric hip fracture .</brief_summary>
	<brief_title>A Study That Will Compare Effect Two Drugs Participants With Low Bone Mass Recent Hip Fracture</brief_title>
	<detailed_description>The study 3 period : screening phase , double-blind , double-dummy treatment phase time randomization 26 week visit , open-label treatment phase approximately 12 month duration , participant continue treatment study drug randomize .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Men postmenopausal woman age â‰¥50 sustain unilateral , fracture trochanteric region Lumbar spine BMD and/or femoral neck BMD and/or total hip BMD measurement contra lateral hip least 2.0 SDs ( standard deviation ) average bone mass young woman men Clinically significant abnormal laboratory value History unresolved skeletal disease affect bone metabolism Polytrauma participants participant fracture one site</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Low bone mass</keyword>
	<keyword>Recent pertrochanteric hip fracture</keyword>
</DOC>